Prelude Therapeutics Q1 2023 net loss $27.7M; cash runway unchanged into Q4 2024

Prelude Therapeutics Inc

2023-Q1 EPS reported -$0.58

Net loss $27.7M ($0.58 loss per share) vs $29.5M ($0.63) in Q1 2022.
Cash, cash equivalents & marketable securities $172.3M; funding operations into Q4 2024.
R&D expenses decreased to $21.8M from $22.8M YoY.
PRT2527 CDK9 inhibitor solid tumor dose escalation complete; RP2D in hematological malignancies expected 2H 2023.
Phase 1 dose escalation of PRT3789 (SMARCA2 degrader) ongoing; oral candidate nomination expected early 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Prelude Therapeutics Inc reported first quarter ended March 31, 2023 results: net income $27.7 million, EPS $0.58 per share.

Period: first quarter ended March 31, 2023
Net income: $27.7 million
EPS: $0.58 per share
Result: reported results

Exact text from the filing

Net Loss: For the three months ended March 31, 2023, net loss was $27.7 million, or $0.58 per share compared to $29.5 million, or $0.63 per share, for the prior year period.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-018477

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.